Metabolites produced as intermediaries or end-products of microbial metabolism provide crucial signals for health and diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD). These metabolites include products of the bacterial metabolism of dietary substrates, modification of host molecules (such as bile acids [BAs], trimethylamine-N-oxide, and short-chain fatty acids), or products directly derived from bacteria. Recent studies have provided new insights into the association between MASLD and the risk of developing chronic kidney disease (CKD). Furthermore, alterations in microbiota composition and metabolite profiles, notably altered BAs, have been described in studies investigating the association between MASLD and the risk of CKD. This narrative review discusses alterations of specific classes of metabolites, BAs, fructose, vitamin D, and microbiota composition that may be implicated in the link between MASLD and CKD.
Citations
Citations to this article as recorded by
Radish Green Extract Attenuates Western Diet-Induced Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice Hye-Bin Lee, Yu Ra Lee, Eunjung Lee, Seong Un Jeong, Jae-Hyun Yoon, Miri Park, Yoonsook Kim, Ho-Young Park Journal of Agricultural and Food Chemistry.2026; 74(1): 874. CrossRef
Multi-omics reveal the key role of gut microbiota metabolism in adenine-induced chronic kidney disease Yijing Xin, Hui Ma, Xiang Li, Ruiyang Sun, Luo Fang, Libin Pan Toxicology and Applied Pharmacology.2026; 509: 117754. CrossRef
Research Progress on the Bile Acid Metabolome in Arteriovenous Fistula Stenosis among Maintenance
Hemodialysis Patients 佩 张 Advances in Clinical Medicine.2026; 16(03): 2204. CrossRef
Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu Frontiers in Medicine.2026;[Epub] CrossRef
Plasma proteome profiling identifies XPNPEP3 as a novel biomarker associated with metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus Hua Ji, Yating Lu, Yichang Liu, Yinguang Jia, Jie Liu, Datong Deng, Mingwei Chen Annals of Medicine.2026;[Epub] CrossRef
Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis Yan Li, Yuyuan Hu, Yuan He, Yuhang Yang, Dingwen Xue, Erkui Xue, Jinghan Jia, Wei Zhang, Jinxi Wang Frontiers in Immunology.2026;[Epub] CrossRef
Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities Xiao-Dong Zhou, Qiong-Yue Fan, Giovanni Targher, Christopher D. Byrne, Wei Xie, Qin-Fen Chen, Yuxing Dong, Fudi Wang, Daolin Tang, Ming-Hua Zheng Med.2026; 7(6): 101099. CrossRef
Classification of intestinal inflammation driven by gut microbiota metabolites: a new paradigm for precision treatment of cardiovascular diseases Dahua Zhao, Yanjun Cui, Zhen Hua Frontiers in Microbiology.2026;[Epub] CrossRef
Bile Acids and the Gut–X Axis: TCM-Mediated Systemic Protection and Therapeutic Opportunities for Multi-Organ Diseases Jialu He, Linjie Qin, Xian Sun Metabolites.2026; 16(6): 366. CrossRef
Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis André O. Soares, Davi A. C. Loli, Gustavo R. Carvalho, Vinicius Daher Alvares Delfino, Paulo Roberto Bignardi Reviews in Endocrine and Metabolic Disorders.2026;[Epub] CrossRef
Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis Martin T. W. Kueh, Jacob Kang Wen Yeo, Yiming Chen, Nicole Ying Zi Chua, Hui Lian Koh, Seng Pei Khaw, Hassan Jabbar, Jiong‐Wei Wang, Kwan Lee, Yip Han Chin, Dan Qin Sun, Alessandro Mantovani, Giovanni Targher, Nicholas W. S. Chew, Xiao‐Dong Zhou, Ming‐Hua Liver International.2026;[Epub] CrossRef
The Relationship Between Adherence to the Mediterranean Diet, Oxidative Stress, Trimethylamine N-Oxide, and Inflammatory Markers in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Saibe Merve Kazdal, Medeni Arpa, Çağlayan Keklikkiran, Sevinç Yücecan Nutrients.2026; 18(14): 2231. CrossRef
Hepatocyte hedgehog signaling controls ferroptosis to alleviate aging-related organ dysfunction Ji Hye Jun, Rajesh Kumar Dutta, Soon-Woo Cho, Rui Yao, Seh Hoon Oh, Zhi Li, Kuo Du, David S. Umbaugh, Nanchao Wang, Yirui Xu, Jingting Li, Lingyan Shi, Jen-Tsan Chi, Junjie Yao, Anna Mae Diehl JCI Insight.2026;[Epub] CrossRef
Bile acid signaling: from dynamic pool composition to inter-organ communication Fuyu Yang, Ting Wei, Kai Liu, Huikuan Chu, Ling Yang Frontiers in Endocrinology.2026;[Epub] CrossRef
Organ crosstalk in kidney diseases: Insights from metabolic, hormonal and nervous regulation Sen Lin, Shirong Zhu, Yi Fu Life Sciences.2026; 404: 124637. CrossRef
Quantifying inequalities and forecasting the burden of chronic kidney disease from 1990 to 2040 Xian Shao, Wenyi Jin, Mingzhen Pang, Ruixuan Chen, Ting Luo, Heping Zhang, Liming Pan, Kexin Ding, Shuxian Ma, Lili Zheng, Baozhen Huang, Pengpeng Ye, Sheng Nie, Xin Xu, Queran Lin iScience.2026; 29(9): 117273. CrossRef
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges Dario Piatto, Delia De Biasio, Francesco Giustino Cesaro, Gianmario Forcina, Vittoria Frattolillo, Antonio Colucci, Fabio Lamberti, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Journal of Clinical Medicine.2025; 14(11): 3911. CrossRef
Altered mitochondrial function: a clue therapeutic strategies between metabolic dysfunction-associated steatotic liver disease and chronic kidney disease? Jiang Bai, Lijuan Zhang, Letian He, Yun Zhou Frontiers in Nutrition.2025;[Epub] CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Quyu Huazhuo Decoction alleviates non-Alcoholic steatohepatitis via remodeling the gut microbiota and regulating bile acid and short-chain fatty acid metabolism Lu Lu, Chengting Wu, Juhong Jia, Yuanqin Du, Yujiao Peng, Hongna Huang, Jingjing Huang, Yaobin Nong Journal of Chromatography B.2025; 1267: 124784. CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano Exploration of Medicine.2025;[Epub] CrossRef
Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications Wenhua Bai, Zheng Zhu Frontiers in Endocrinology.2025;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis are Associated with Advanced Cardiovascular-Kidney-Metabolic Syndrome in Chinese and US Populations Shidi Hu, Dongmei Wang, Qingtao Yu, Zhi Chen, Weiguo Lu, Yuan Meng, Xuetao Peng, Lan Liu, Heng Wan, Jie Shen Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4699. CrossRef
Background/Aims Despite the high efficacy of direct-acting antivirals (DAAs), approximately 1–3% of hepatitis C virus (HCV) patients fail to achieve a sustained virological response. We conducted a nationwide study to investigate risk factors associated with DAA treatment failure. Machine-learning algorithms have been applied to discriminate subjects who may fail to respond to DAA therapy.
Methods We analyzed the Taiwan HCV Registry Program database to explore predictors of DAA failure in HCV patients. Fifty-five host and virological features were assessed using multivariate logistic regression, decision tree, random forest, eXtreme Gradient Boosting (XGBoost), and artificial neural network. The primary outcome was undetectable HCV RNA at 12 weeks after the end of treatment.
Results The training (n=23,955) and validation (n=10,346) datasets had similar baseline demographics, with an overall DAA failure rate of 1.6% (n=538). Multivariate logistic regression analysis revealed that liver cirrhosis, hepatocellular carcinoma, poor DAA adherence, and higher hemoglobin A1c were significantly associated with virological failure. XGBoost outperformed the other algorithms and logistic regression models, with an area under the receiver operating characteristic curve of 1.000 in the training dataset and 0.803 in the validation dataset. The top five predictors of treatment failure were HCV RNA, body mass index, α-fetoprotein, platelets, and FIB-4 index. The accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of the XGBoost model (cutoff value=0.5) were 99.5%, 69.7%, 99.9%, 97.4%, and 99.5%, respectively, for the entire dataset.
Conclusions Machine learning algorithms effectively provide risk stratification for DAA failure and additional information on the factors associated with DAA failure.
Citations
Citations to this article as recorded by
Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Cheng Liang, Yi‐Hung Lin, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu Alimentary Pharmacology & Therapeutics.2026; 63(8): 1119. CrossRef
The complexities of the pharmacotherapeutic management of chronic hepatitis C virus infection in hepatocellular carcinoma patients Nicola Schiano Moriello, Biagio Pinchera, Ivan Gentile Expert Opinion on Pharmacotherapy.2026; 27(8): 625. CrossRef
Cross-Model Explainability Consistency in Hepatitis C Stage Classification: A SHAP, LIME, and Counterfactual Analysis Across Five Machine Learning Architectures Khalid Alalawi Diagnostics.2026; 16(14): 2197. CrossRef
AI-Driven Approaches for the Detection, Classification, and Surveillance of Viral Pathogens: Current Advances, Challenges, and Future Directions Hathem Khelil, Rosanna Palumbo, Giovanni N. Roviello Pathogens.2026; 15(7): 761. CrossRef
AI-driven diagnostic and prognostic systems for liver diseases: A comprehensive review of machine learning applications in clinical hepatology and transplantation medicine C Y Kalpavi, B M Sujatha, V Deepthi, K Sindhu Journal of Liver Transplantation.2026; 24: 100388. CrossRef
CATS-BIT-ME Score: A Machine Learning and Conventional Risk Model for Prognosis in Hepatocellular Carcinoma Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, I-Cheng Lee, Jiing-Chyuan Luo, Yi-Hsiang Huang, Teh-Ia Huo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su Gastro Hep Advances.2026; 5(11): 101063. CrossRef
Artificial intelligence in Latin American hepatology: current evidence, implementation barriers, and strategic priorities Ezequiel Ridruejo, Andreas Teufel, Mario Alvares-da-Silva, Juan Turnes Annals of Hepatology.2026; : 102432. CrossRef
AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim Journal of Hepatology.2025; 82(3): 456. CrossRef
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan Szu‐Jen Wang, Chung‐Feng Huang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Ming‐Jong Bair, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yu The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Explainable machine learning for the assessment of donor grafts in liver transplantation Liang Zhixing, Ye Linsen, Jiang Peng, Dong Siyi, Yu Haoyuan, Li Kun, Li Siqi, Hu Yongwei, Zhang Mingshen, Liu Wei, Li Hua, Yi Shuhong, Chen Guihua, Xu Xiao, Zheng Shusen, Yang Yang Hepatology Research.2025; 55(6): 908. CrossRef
Role of risk factors and their variable types in predicting noise-induced hearing loss using artificial intelligence algorithms Zhengheng Zhang, Longteng Jiang, Meibian Zhang, Yuan Pan, Jinnan Zheng, Anqi Liu, Weijiang Hu, Xin Jin Hearing Research.2025; 465: 109353. CrossRef
Artificial Intelligence and Machine Learning Applications in Liver Disease Bhargav Vemulapalli, Meghana Ghattu, Kavya Atluri, James Lee, Vinod Rustgi Clinics in Liver Disease.2025; 29(4): 755. CrossRef
Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response Aya I. Abdelaziz, Eman Abdelsameea, Sara A. Wahdan, Doaa Elsherbiny, Zeinab Zakaria, Samar S. Azab Clinical and Experimental Medicine.2025;[Epub] CrossRef
Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Elimination Daniela Toma, Lucreția Anghel, Diana Patraș, Anamaria Ciubară Viruses.2025; 17(8): 1069. CrossRef
Nationwide hepatitis C virus microelimination in uremic patients undergoing maintenance hemodialysis in Taiwan Chung-Feng Huang, Po-Cheng Liang, Yu-Ju Wei, Chao-Chun Wu, Shi-Lun Wei, Li-Ju Lin, Pei-Chun Hsieh, Tsui-Hsia Hsu, Maggie Shu-Mei Hsu, Ya-Xin Luo, Hsi-Chieh Chen, Tsu-Yun Ho, Shao-Hsuan Lin, Chia-Ling Liu, Kuo-Pen Cheng, John W. Ward, Ming-Lung Yu Journal of the Formosan Medical Association.2025; 124: S102. CrossRef
Identifying new strategies to combat cytomegalovirus by integrating existing and innovative approaches in diagnosis and treatment Nargiz Imamova, Ayten Feteliyeva, Adil M. Allahverdiyev Future Virology.2025; 20(10): 379. CrossRef
Artificial intelligence in hepatology: A comprehensive scoping review of clinical applications, challenges, and future directions Kirolos Eskandar iLIVER.2025; 4(4): 100205. CrossRef
Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan Chin-Wei Chang, Wei-Fan Hsu, Kuo-Chih Tseng, Chi-Yi Chen, Pin-Nan Cheng, Chao-Hung Hung, Ching-Chu Lo, Ming-Jong Bair, Chien-Hung Chen, Pei-Lun Lee, Chun-Yen Lin, Hsing-Tao Kuo, Chun-Ting Chen, Chi-Chieh Yang, Jee-Fu Huang, Chi-Ming Tai, Jui-Ting Hu, Chih Digestive Diseases and Sciences.2024; 69(9): 3501. CrossRef
Bridging Real-World Data Gaps: Connecting Dots Across 10 Asian Countries Guilherme Silva Julian, Wen-Yi Shau, Hsu-Wen Chou, Sajita Setia JMIR Medical Informatics.2024; 12: e58548. CrossRef
The role of artificial intelligence in the management of liver diseases Ming‐Ying Lu, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(11): 962. CrossRef
Real-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross-Sectional, Multicenter Study Khalid M. Al-Naamani, Heba Omar, Said A. Al Busafi, Halima H. Al Shuaili, Zakariya Al-Naamani, Murtadha Al-Khabori, Elias A. Said, Abdullah H. AlKalbani, B. R. Kamath, Bashar Emad, Shahina Daar, Lolo Alhajri, Alya AlKalbani, Zainab AlFarsi, Haifa Alzuhaib Journal of Clinical Medicine.2024; 13(23): 7411. CrossRef
Accuracy and readability of LLM-generated responses for gout management: a benchmark study based on ACR guidelines Zhuhai Shao, Yiwen Zhang, Bingfei Cheng, Fang Zhang, Xuhua Zhu, Zhongchao Wang, Yangang Wang, Lili Xu, Zepeng Mu Clinical Rheumatology.2026; 45(6): 3685. CrossRef
Revolutionizing MASLD: How Artificial Intelligence Is Shaping the Future of Liver Care Nicola Pugliese, Arianna Bertazzoni, Cesare Hassan, Jörn M. Schattenberg, Alessio Aghemo Cancers.2025; 17(5): 722. CrossRef
Large language models in thyroid diseases: Opportunities and challenges Yiwen Zhang, Pengfei Li, Lili Xu, Xuejuan Zhang, Hongwei Ji, Yangang Wang EngMedicine.2025; 2(2): 100076. CrossRef
Preliminary fatty liver disease grading using general-purpose online large language models: ChatGPT-4 or Bard? Yiwen Zhang, Hanyun Liu, Bin Sheng, Yih Chung Tham, Hongwei Ji Journal of Hepatology.2024; 80(6): e279. CrossRef
The performance of large language model-powered chatbots compared to oncology physicians on colorectal cancer queries Shan Zhou, Xiao Luo, Chan Chen, Hong Jiang, Chun Yang, Guanghui Ran, Juan Yu, Chengliang Yin International Journal of Surgery.2024; 110(10): 6509. CrossRef
First
Prev
